Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance
Department of Biochemistry and Molecular Pharmacology
Medical Subject Headings
*Drug Design; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Kinetics; Microsomes; Protein Binding; Static Electricity; Substrate Specificity
The rapid evolution of HIV under selective drug pressure has led to multidrug resistant (MDR) strains that evade standard therapies. We designed highly potent HIV-1 protease inhibitors (PIs) using the substrate envelope model, which confines inhibitors within the consensus volume of natural substrates, providing inhibitors less susceptible to resistance because a mutation affecting such inhibitors will simultaneously affect viral substrate processing. The designed PIs share a common chemical scaffold but utilize various moieties that optimally fill the substrate envelope, as confirmed by crystal structures. The designed PIs retain robust binding to MDR protease variants and display exceptional antiviral potencies against different clades of HIV as well as a panel of 12 drug-resistant viral strains. The substrate envelope model proves to be a powerful strategy to develop potent and robust inhibitors that avoid drug resistance.
Rights and Permissions
Citation: Chem Biol. 2013 Sep 19;20(9):1116-24. doi: 10.1016/j.chembiol.2013.07.014. Epub 2013 Sep 5. Link to article on publisher's site
Nalam, Madhavi N. L.; Ali, Akbar; Reddy, G. S. Kiran Kumar; Cao, Hong; Anjum, Saima G.; Altman, Michael D.; Yilmaz, Nese Kurt; Tidor, Bruce; Rana, Tariq M.; and Schiffer, Celia A., "Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance" (2013). Biochemistry and Molecular Pharmacology Publications and Presentations. 212.